title: Melanoma: immune checkpoint blockade story gets better.
authors.affiliation: Medical Oncology, University of Washington, Seattle, WA, USA; Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
authors.forename: Shailender
authors.initials: S
authors.lastname: Bhatia
authors.affiliation: Medical Oncology, University of Washington, Seattle, WA, USA; Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address: jat@uw.edu.
authors.forename: John A
authors.initials: JA
authors.lastname: Thompson
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab